ABSTRACT
Objective To observe the effect of Anshen Bunao syrup combined with escitalopram oxalate on nervous function defect in patients with post stroke depression,and to provide effective treatment for the disease with integrated traditional Chinese and western medicine.Methods 257 patients with post stroke depression were selected,and they were divided into observation group(130 cases) and control group(127 cases) according to the digital table.The two groups were given the same basic treatment,the control group was given escitalopram oxalate,and the observation group was given Anshen Bunao syrup combined with escitalopram oxalate.The NIHSS and HAMD scores of the two groups were evaluated before and 2,4,8 weeks after treatment.The adverse drug reaction was observed during the treatment period.The treatment effect was determined according to the HAMD reduction rate after 8 weeks.Results 2,4 and 8 weeks after treatment,the NIHSS scores of the observation group were (18.9 ±6.2)points,(15.6 ± 6.4) points,(12.2 ± 4.3) points,respectively,which were lower than (22.5 ± 7.1) points before treatment (t =4.355,8.230,14.148,all P ＜ 0.05).4 and 8 weeks after treatment,the NIHSS scores of the control group were (17.2 ± 7.5) points,(14.4 6.6) points,respectively,which were lower than (22.1 ± 8.4) points before treatment (t =4.904,8.123,all P ＜ 0.05).4 and 8 weeks after treatment,the NIHSS scores of the observation group were lower than those of the control group(t =3.640,1.855,all P ＜ 0.05).2,4 and 8 weeks after treatment,the HAMD scores of the two groups[(15.4 ± 5.1) points,(14.0 ± 5.2) points,(10.5 ± 4.7) points and (14.8 ± 4.6) points,(12.4 ± 5.8) points,(7.9 ± 3.8) points] were lower than before treatment [(23.9 ± 4.7) points,(23.2 ± 5.4) points] (t =13.501,15.539,26.419,13.812,4.748,4.748,all P ＜ 0.05).8 weeks after treatment,the HAMD score of the observation group was lower than that of the control group (t =3.640,P ＜ 0.05).8 weeks after treatment,the treatment effect was determined according to the HAMD reduction rate,the total effective rates of the observation group and the control group were 95.4％ (124/130),91.3 ％ (116/127),respectively.The curative effect of the observation group was better than the control group(Z =3.104,P ＜ 0.05).In the course of treatment,the incidence rate of adverse drug reactions of the control group was 6.30％ (8/127),which of the observation group was 5.38％ (7/130),there was no statistically significant difference between the two groups(x2 =0.098,P ＞ 0.05).Conclusion Anshen Bunao syrup combined with escitalopram oxalate can improve the nervous function defect in patients with post stroke depression,and the incidence rate of adverse drug reactions is low,which has good clinical value.
ABSTRACT
Objective To study the clinical effect of escitalopram oxalate in treating patients with depression accompanied with anxiety disorder.Methods Sixty-four patients with depression accompanied with anxiety disorder (met DSM-IV diagnostic criteria)were randomly divided into study group (n =32)who were treated with escitalo-pram oxalate 5-20mg/d and control group (n =32)with mirtazapine 15-45 for eight weeks.Clinical effect was evalua-ted with the Hamilton Depression Scale (HAMD)and the Hamilton Anxiety Scale (HAMA)as well as the adverse reactions with the Treatment Emergent Symptom Scale (TESS).Results There were no statistically significant differ-ences (P >0.05)in HAMD and HAMA scores between the study group and control group before treatment,but after treatment for 8 weeks,HAMD score showed statistically significant difference (P =0.000)and the difference of HAMA score was statistically significant (P =0.010).The total effective rate of the study group was 93.8%,which of the control group was 87.5%,the clinical effect had no statistically significant difference (P =0.391 ).The study group and the control group had equal effect,and there were no serious adverse reactions.Conclusion Escitalopram oxalate has high anti-depressant and anxiolytic effect,fewer adverse reactions,good tolerability and compliance,there-fore,escitalopram oxalate can be popularized in treating patients with depression accompanied with anxiety disorder.
ABSTRACT
Objective:To evaluate the cost-effectiveness of duloxetine, escitalopram oxalate and mirtazapine in the treatment of depression. Methods:Totally 120 cases of patients were randomly divided into three group. Group A was given duloxetine 40mg twice a day, group B was with escitalopram oxalate at the initial dose of 10mg per day, and up to 20mg per day in 2 weeks, and group C was treated with mirtazapine 30mg per day. The treatment course was eight weeks. At the 1st, 2nd, 3rd, 4th and 8th weekends after the treatment, Hamilton depression scale ( HAMD) was used to evaluate the total effective rate, and treatment emergent symptom scale ( TESS) was applied to assess the adverse drug reactions. Results:The total effective rate of group A, B and C was 87. 5%,90% and 92. 5% with the cost of 23 822. 22 yuan,33 866. 02 yuan and 19 586. 62 yuan, respectively. The cost-effectiveness ratio respectively was 27 225, 37 629 and 21 175. The incidence of adverse reactions respectively was 30%, 30% and 17. 5%. Conclusion:The cost-effectiveness of mirtazapine is the lowest in the treatment of depression, which can be considered as the best treatment regimen.
ABSTRACT
Objective To explore neuroprotective effect of escitalopram oxalate on cerebral ischemia reperfusion in injury rats and its possible mechanism,thus provide experimental evidence for the use of the drug in the clinical treatment of ischemic cerebrovascular disease.Methods 160 male rats of SD were selected and randomly divided into three groups:sham operation group(Sham group),negative control group(NS group),intervention group(CIT group,for 14 days and 21 days).Focal middle cerebral artery occlusion model(MCAO)of rats were constructed.Neurological deficit of rats in each group were evaluated by modified neurological severity score(mNSS)scale.Microvessel diameter,density,and total area of each group angiogenesis in cerebral ischemic area were observed by Laser cofocal technology after 14 days and 21 days at different time points;the plasma concentrations of VEGF were detected by ELASA,and expression levels of VEGF were detected by immunohistochemical assay and Western blot in each group,to explore its possible mechanism of molecular biology.Results After modeling,neurological deficit of intervention group for 14 days and 21 days were improved significantly.The indicators were as follows:scores of mNSS in NS group(6.57 ±1.13)was significantly higher than(4.39 ±0.92)in intervention group for 14 days(P<0.05);scores of mNSS in intervention group(3.23 ±0.55)for 21 days was significantly lower than(4.14 ±0.74)in intervention group for 14 days(P<0.01).Confocal 3D imaging results after 14 days showed:microvascular total area was significantly lager which illustrated that the effect of drug intervention for 14 days started to work over time.Plasma concentrations and expression levels of VEGF in intervention group for 14 days and 21 days were higher than those in Sham group,NS group.VEGF protein expression of cerebral ischemia tissues in intervention group for 21 days were higher than that of 14 days(P<0.01).Conclusion Escitalopram oxalate could significantly reduce cerebral ischemia and reperfusion in rats nerve injury and improve neurological function,which has a neuroprotective effect,the effect of drug intervention gradually increases over time,and the possible mechanism of which is related to angiogenesis mediated by VEGF.
ABSTRACT
OBJECTIVE: To establish an HPLC method and potentiometric titration method for the determination of escitalopram oxalate and its related substances for quality control.
ABSTRACT
A Simple, efficient and reproducible reverse phase high performance liquid chromatographic method was developed and validated for the Simultaneous determination of Escitalopram oxalate and Clonazepam in combined dosage form. The separation was effected on a Hypersil ODS C18 column (250mm X 4.6mm; 5μ) using a mobile phase mixture of buffer and acetonitrile in a ratio of 50:50 v/v at a flow rate of 1.0ml/min. The detection was made at 240nm. The retention time of Escitalopram oxalate and Clonazepam was found to be 2.840± 0.007min and 4.007±0.006 min. Calibration curve was linear over the concentration range of 20-120μg/ml and 1-6μg/ml for Escitalopram oxalate and Clonazepam. All the analytical validation parameters were determined and found in the limit as per ICH guidelines, which indicates the validity of the method. The developed method is also found to be precise, accurate, specific, robust and rapid for the simultaneous determination of Escitalopram oxalate and Clonazepam in tablet dosage forms.
ABSTRACT
A Simple, efficient and reproducible reverse phase high performance liquid chromatographic method was developed and validated for the Simultaneous determination of Escitalopram oxalate and Clonazepam in combined dosage form. The separation was effected on a Hypersil ODS C18 column (250mm X 4.6mm; 5μ) using a mobile phase mixture of buffer and acetonitrile in a ratio of 50:50 v/v at a flow rate of 1.0ml/min. The detection was made at 240nm. The retention time of Escitalopram oxalate and Clonazepam was found to be 2.840± 0.007min and 4.007±0.006 min. Calibration curve was linear over the concentration range of 20-120μg/ml and 1-6μg/ml for Escitalopram oxalate and Clonazepam. All the analytical validation parameters were determined and found in the limit as per ICH guidelines, which indicates the validity of the method. The developed method is also found to be precise, accurate, specific, robust and rapid for the simultaneous determination of Escitalopram oxalate and Clonazepam in tablet dosage forms.
ABSTRACT
OBJECTIVE:To study the pharmacokinetics of escitalopram oxalate tablets in human body.METHODS:Es-citalopram oxalate tablets were administered orally at a single dose of30mg to10healthy subjects respectively,the plasma concentration of escitalopram oxalate was determined by HPLC method,the pharmacokinetic parameter was fitted with3p97software.RESULTS:The concentration-time curve of escitalopram oxalate tablets was in line with the two-compartment model,the main pharmacokinetics parameters of escitalopram oxalate were as follows,the C max was(42.73?10.19)?g?L,t max was(2.90?0.32)h,t 1/2 was(35.34?7.78)h,AUC 0～132 was(1241.5?194.3)(?g?h)/L and the AUC 0～∞ was(1327.5?210.5)(?g?h)/L.CONCLUSION:The study on pharmacokinetics can be used as a reference in the clinical medication.